NCT01800695 (Clinical Trial / ABT-414)

Study Title
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme (NCT01800695)

Trial Description
This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme. [1]

This trial is sponsored by AbbVie.

Study Data

  • Condition: Glioblastoma Multiforme
  • Interventions:
    • Drugs used in this trial
      • ABT-414
      • Temozolomide (Temodar®; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.)
      • Radiation: Whole Brain Radiation
  • Phase: I
  • Estimated Enrollment: 202
  • Start: April 2013
  • Estimated Completion: June 2017
  • Last Verified: July 2017

Study Schematic 

NCT01800695

Return to drug map

Last Editorial review: August 28, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.